$829.00 – $3,579.00
Imfinzi works by helping the immune system attack cancer cells.
Imfinzi is indicated for:
– Unresectable locally advanced non-small cell lung cancer in adult patients who have not shown disease progression following platinum-based chemoradiation;
– First-line treatment of advanced small cell lung cancer in combination with etoposide and carboplatin or cisplatin;
– Locally advanced or metastatic biliary tract cancer in combination with chemotherapy.
Durvalumab is a fully human, high-affinity monoclonal antibody, immunoglobulin G1 kappa (IgG1κ), that selectively blocks the interaction of PD-L1 with PD-1 or CD80 (B7.1), while sparing the interaction between PD-1 and PD-L2.
Durvalumab does not induce antibody-dependent cellular cytotoxicity. Selective blockade of interactions between PD-L1 and PD-1 and PD-L1 and CD80 leads to an enhanced antitumor immune response, which can lead to tumor elimination. In preclinical studies, PD-L1 blockade led to increased T-lymphocyte activation and a decrease in tumor size.
Active ingredient: Durvalumab
Storage temperature 2-8 degrees
Prescription medicine
| Дозировка | 120 MG/2.4 ML, 500 MG/10 ML |
|---|
